SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI is drawing significant community attention as investors debate whether current price consolidation offers a prime entry point or signals further downside. Supporters are heavily focused on the token's role within the Base ecosystem and potential utility integrations, while discussion remains split between calls for a massive short squeeze and concerns regarding sustained volume.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is drawing significant community attention as investors weigh the stock's sensitivity to geopolitical escalations in the Middle East and ongoing supply concerns in the Strait of Hormuz. Conversations are dominated by debates over whether current price action is being manipulated by broader market forces, with many participants actively looking toward upcoming earnings as a potential catalyst for a breakout from current technical support levels.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is trending as investors focus on the company's strategic pivot toward AI infrastructure following its acquisition of Northern Data, with community members actively discussing its massive GPU capacity, Tether's backing, and the potential for a significant short squeeze. Despite stagnant price action, supporters highlight bullish catalysts like upcoming Q2 earnings guidance and potential government cloud contracts as key drivers for long-term repricing.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors favor its dominant position in the metabolic drug market, bolstered by strong performance from Mounjaro and Zepbound alongside strategic expansions into neuroscience and oncology. The community is actively discussing the companys competitive edge against rival oral treatments, while institutional capital flows into the stock as part of a broader rotation from high-volatility tech sectors into defensive, growth-oriented healthcare leaders.

American Bitcoin Corp. engages in the management of a bitcoin accumulation platform. It offers exposure to bitcoin through an industry-first business model that integrates scaled self-mining operations with disciplined accumulation strategies. The company was founded by Eric Trump and Donald John Trump Jr. on October 3, 2018 and is headquartered in Miami, FL.

American Bitcoin Corp. - Ordinary Shares - Class A

American Bitcoin Corp.

American Bitcoin Corp. is experiencing intense selling pressure as investors react to the company's approved reverse stock split and ongoing concerns regarding heavy dilution. Community discourse is sharply divided between those warning of a potential delisting or further price erosion and bargain hunters who believe the stock's significant Bitcoin treasury holdings offer a contrarian opportunity.

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is surging on significant investor interest following an oversubscribed private placement designed to advance its clinical pipeline. The community is actively debating the stock's massive volatility and momentum, with many users focused on potential short squeezes while others warn of the risks associated with future dilution.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Singapore.

Seagate Technology Holdings Plc

Seagate Technology is trending as part of a broader, high-momentum rally in memory and storage stocks driven by persistent AI infrastructure demand and tight supply constraints. Community sentiment remains focused on the sector's long-term potential as a critical AI bottleneck, though traders are actively debating the sustainability of the current price surge and monitoring for potential profit-taking.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is trending as investors focus on the company's strong clinical pipeline in thyroid eye disease and potential market share capture against established competitors like Tepezza. The community is actively discussing the company's progress toward commercialization, recent institutional accumulation, and the potential for M&A activity given the firm's strategic positioning and clinical milestones.

ETF Opportunities Trust - Roundhill T-REX 2X Long DRAM Daily Target ETF

T-REX 2X Long DRAM Daily Target ETF

Investors are actively debating the viability of RAM, a newly launched 2X leveraged ETF tracking the semiconductor memory sector, as it experiences extreme volatility following its debut. While some market participants are aggressively scaling positions to capitalize on the AI-driven memory supercycle, others express deep skepticism regarding the risks of leveraged decay and the long-term sustainability of the semiconductor rally.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Investors are closely monitoring Luckin Coffee for a potential rebound as the stock faces downward pressure amid broader Chinese equity volatility. The community remains focused on the company's aggressive international store expansion and the impact of the recently authorized share repurchase program on long-term value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business...

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results PR Newswire CARMIEL, Israel, March...

Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026

Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business...

PLX Shares Jump 13% On EMA Committee’s Turnaround On New Dosing Regimen For Fabry Disease Therapy

Equity

The Committee for Medicinal Products for Human Use recommended approval of the 2mg/kg every-4-weeks dosing regimen in Fabry disease adult patients.


PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. (Protalix or the Company) (NYSE...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Protalix BioTherapeutics Stock Tumbled 28% Today: Why The Latest CHMP Opinion Is Sparking Concerns Among Investors?

However, Protalix CEO said that the results of the review do not change the priority of the company to reduce treatment burden for patients with Fabry disease.

Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead

Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a higher bid or FDA-driven gains.

Pluxee shares jump 11% on strong Q1 operating revenue growth

Investing.com -- Pluxee NV (EPA:PLX) reported 12.1% organic growth in first-quarter operating revenue, beating market expectations, and sending its shares soaring 11% in European trading Wednesday.

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.

Protalix BioTherapeutics Inc.

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is pacing for a losing week as a semiconductor ($SMH) sell-off has dragged the market lower amid growing doubts about AI spending. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$2.38
Prev Close	$2.31
Open	$2.27
Dividend Yield	0.00%
50-Day Moving Average	$2.13
Beta	0.89
Avg. Volume	695,041.19
PE Ratio	12.98

52-Week High	$3.19
52-Week Low	$1.41
Market Capitalization	$186.12M
EPS (Annual)	-$0.0841
Price to Book	2.85
Revenue Per Employee	$233,380.53

Feed

News

Sentiment

Earnings

Fundamentals

Info

PLXProtalix BioTherapeutics Inc.

Latest PLX News